How should patients with completely resected gastrointestinal stromal tumours (GIST) be followed up?;Welche form der nachsorge ist bei patienten mit R0-resezierten gastrointestinalen stromatumoren (GIST) sinnvoll?

Zentralblatt fur Chirurgie

Volumn 130, Issue 6, 2005, Pages 554-561

  Stelzner, S ^a,c   Antoni, C ^a   Haroske, G ^a   Jacobasch, L ^b   Erk, J U ^b   Ludwig, K ^a  

^a DRESDEN UNIVERSITY OF TECHNOLOGY   (Germany)

^b UNIVERSITY HOSPITAL CARL GUSTAV CARUS   (Germany)

^c ACADEMIC TEACHING HOSPITAL DRESDEN FRIEDRICHSTADT   (Germany)

Author keywords

Follow up; GIST; Imatinib mesylate; Recurrence

Indexed keywords

IMATINIB;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; COST EFFECTIVENESS ANALYSIS; DIAGNOSTIC PROCEDURE; ENDOSCOPIC ECHOGRAPHY; FEMALE; FOLLOW UP; GASTROINTESTINAL ENDOSCOPY; GASTROINTESTINAL STROMAL TUMOR; HIGH RISK PATIENT; HUMAN; MALE; TUMOR RECURRENCE; ULTRASOUND;

ADULT; AFTERCARE; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; COST-BENEFIT ANALYSIS; ENDOSCOPY, GASTROINTESTINAL; ENDOSONOGRAPHY; FEMALE; FOLLOW-UP STUDIES; GASTROINTESTINAL STROMAL TUMORS; HUMANS; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; PIPERAZINES; PYRIMIDINES;

EID: 29844433932     PISSN: 0044409X     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2005-918182     Document Type: Article

References (38)

1. Bucher P, Taylor S, Villiger P, Morel P, Brundler MA. Are there any prognostic factors for small intestinal stromal tumors? Am J Surg 2004; 187: 761-766
2. Bümming P, Andersson J, Meis-Kindblom JM, Klingenstierna H, Engström K, Stierner U, Wängberg B, Jansson S, Ahlman H, Kindblom LG, Nilsson B. Neoadjuvant, adjuvant and palliative treatment of gastrointestinal stromal tumours (GIST) with imatinib: a centre-based study of 17 patients. Br J Cancer 2003; 89: 460-464
3. Cormier JN, Patel SR, Pisters PWT. Gastrointestinal stromal tumors: rationale for surgical adjuvant trials with imatinib. Curr Oncol Rep 2002; 4: 504-509
4. Crosby JA, Catton CN, Davis A, Couture J, O'Sullivan B, Kandel R, Swallow CJ. Malignant gastrointestinal stromal tumors of the small intestine: a review of 50 cases from a prospective database. Ann Surg Oncol 2001; 8: 50-59
5. Davila RE, Faigel DO. GI stromal tumors. Gastrointest Endosc 2003; 58: 80-88
6. DeMatteo RP. The GIST of targeted cancer therapy: a tumor (Gastrointestinal stromal tumor), a mutated gene (c-kit), and a molecular inhibitor (STI571). Ann Surg Oncol 2002; 9: 831-839
7. DeMatteo RP, Heinrich MC, El-Rifai WM, Demetri G. Clinical management of gastrointestinal stromal tumors: before and after STI-571. Hum Pathol 2002; 33: 466-477
8. DeMatteo RP, Lewis JJ, Leung D, Mudan SS, Woodruff JM, Brennan MF. Two hundred gastrointestinal stromal tumors. Recurrence patterns and prognostic factors for survival. Ann Surg 2000; 231: 51-58
9. Demetri GD, Baker LH, Beech D, Benjamin R et al. Practice guidelines in oncology: gastrointestinal stromal tumors (GIST). 2004; www.nccn.org/ physician_gls/f_guidelines.html
10. Demetri GD, Mehren M von, Blanke CD, van den Abbeele AD, Eisenberg B, Roberts PJ, Heinrich MC, Tuveson DA, Singer S, Janicek M, Fletcher JA, Silverman SG, Silberman SL, Capdeville R, Kiese B, Peng B, Dimitrijevic S, Druker BJ, Corless C, Fletcher CDM, Joensuu H. Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N Engl J Med 2002; 347: 472-480
11. Emory TS, Sobin LH, Lukes L, Lee DH, O'Leary TJ. Prognosis of gastrointestinal smooth-muscle (stromal) tumors. Dependence on anatomic site. Am J Surg Pathol 1999; 23: 82-87
12. Evans HL. Smooth muscle tumors of the gastrointestinal tract. A study of 56 cases followed for a minimum of 10 years. Cancer 1985; 56: 2242-2250
13. Fletcher CDM, Berman JJ, Corless C, Gorstein F, Lasota J, Longley BJ, Miettinen M, O'Leary TJ, Remotti H, Rubin BP, Shmookler B, Sobin LH, Weiss SW. Diagnosis of gastrointestinal stromal tumors: a consensus approach. Hum Pathol 2002; 33: 459-465
14. Franquemont DW. Differentiation and risk assessment of gastrointestinal stromal tumors. Am J Clin Pathol 1995; 103: 41-47
15. Hasegawa T, Matsuno Y, Shimoda T, Hirohashi S. Gastrointestinal stromal tumor: consistent CD117 immunostaining for diagnosis, and prognostic classification based on tumor size and MIB-1 grade. Hum Pathol 2002; 33: 669-676
16. Hermanek P, Junginger T, Hossfeld DK, Müller RP, Fölsch UR. Nachsorge und Rehabilitation bei Patienten mit gastrointestinalen Tumoren. Dtsch Ärztebl 1999; 96A: 2084-2088
17. Hirota S, Isozaki K, Moriyama Y, Hashimoto K, Nishida T, Ishiguro S, Kawano K, Hanada M, Kurata A, Takeda M, Tunio GM, Matsuzawa Y, Kanakura Y, Shinomura Y, Kitamura Y. Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors. Science 1998; 279: 577-580
18. Hohenberger P. Neue Konzepte der chirurgischen Therapie gastrointestinaler Stromatumoren (GIST). Viszeralchirurgie 2003; 38: 379-386
19. Kim CJ, Day S, Yeh KA. Gastrointestinal stromal tumors: analysis of clinical and pathologic factors. Am Surg 2001; 67: 135-137
20. Lehnert T. Gastrointestinal sarcoma (GIST) - a review of surgical management. Ann Chir Gynaecol 1998; 87: 297-305
21. Mechtersheimer G, Egerer G, Hensel M, Rieker RJ, Libicher M, Lehnert T, Penzel R. Gastrointestinal stromal tumours and their response to treatment with the tyrosine kinase inhibitor imatinib. Virchows Arch 2004; 444: 108-118
22. Miettinen M, Blay JY, Sobin LH. Mesenchymal tumours of the stomach. In: Hammilton SR, Aaltonen LA (eds.). World Health Organization classification of tumours. Pathology and genetics of the digestive system. IARC Press, Lyon 2000; 62-65
23. Miettinen M, El-Rifai W, Sobin LH, Lasota J. Evaluation of gastrointestinal stromal tumors: a review. Hum Pathol 2002; 33: 478-483
24. Miettinen M, Furlong M, Sarlomo-Rikala M, Burke A, Sobin LH, Lasota J. Gastrointestinal stromal tumors, intramural leiomyomas, and leiomyosarcomas in the rectum and anus. A clinicopathologic, immunohistochemical, and molecular genetic study of 144 cases. Am J Surg Pathol 2001; 25: 1121-1133
25. Miettinen M, Kopczynski J, Makhlouf HR, Sarlomo-Rikala M, Gyorffy H, Burke A, Sobin LH, Lasota J. Gastrointestinal stromal tumors, intramural leiomyomas, and leiomyosarcomas in the duodenum. A clinicopathologic, immunohistochemical, and molecular genetic study of 167 cases. Am J Surg Pathol 2003; 27: 625-641
26. Miettinen M, Sarlomo-Rikala M, Sobin LH, Lasota J. Gastrointestinal stromal tumors and leiomyosarcomas in the colon. A clinicopathologic, immunohistochemical, and molecular genetic study of 44 cases. Am J Surg Pathol 2000; 24: 1339-1352
27. Mudan SS, Conlon KC, Woodruff JM, Lewis JJ, Brennan MF. Salvage surgery for patients with recurrent gastrointestinal sarcoma: Prognostic factors to guide patient selection. Cancer 2000; 88: 66-74
28. Ng EH, Pollock RE, Munsell MF, Atkinson EN, Romsdahl MM. Prognostic factors influencing survival in gastrointestinal leiomyosarcomas. Implications for surgical management and staging. Ann Surg 1992; 215: 68-77
29. Pierie JP, Choudry U, Muzikansky A, Yeap BY, Souba WW, Ott MJ. The effect of surgery and grade on outcome of gastrointestinal stromal tumors. Arch Surg 2001; 136: 383-389
30. Reith JD, Goldblum JR, Lyles RH, Weiss SW. Extragastrointestinal (soft tissue) stromal tumors: an analysis of 48 cases with emphasis on histologic predictors of outcome. Mod Pathol 2000; 13: 577-585
31. Samiian L, Weaver M, Velanovich V. Evaluation of gastrointestinal stromal tumors for recurrence rates and patterns of long-term follow-up. Am Surg 2004; 70: 187-191
32. Sarlomo-Rikala M, Kovatich AJ, Barusevicius A, Miettinen M. CD117: a sensitive marker for gastrointestinal stromal tumors that is more specific than CD34. Mod Pathol 1998; 11: 728-734
33. Scaife CL, Hunt KK, Patel SR, Benjamin RS, Burgess MA, Chen LL, Trent J, Raymond AK, Cormier JN, Pisters PWT, Pollock RE, Feig BW. Is there a role for surgery in patients with "unresectable" cKIT + gastrointestinal stromal tumors treated with imatinib mesylate? Am J Surg 2003; 186: 665-669
34. Singer S, Rubin BP, Lux ML, Chen CJ, Demetri GD, Fletcher CDM, Fletcher JA. Prognostic value of KIT mutation type, mitotic activity, and histologic subtype in gastrointestinal stromal tumors. J Clin Oncol 2002; 20: 3898-3905
35. van Oosterom AT, Judson I, Verweij J, Stroobants S, diPaola ED, Dimitrijevic S, Martens M, Webb A, Sciot R, van Glabbeke M, Silberman S, Nielsen OS. Safety and efficacy of imatinib (STI571) in metastatic gastrointestinal stromal tumours: a phase I study. Lancet 2001; 358: 1421-1423
36. Wong NACS, Young R, Malcomson RDG, Nayar AG, Jamieson LA, Save VE, Carey FA, Brewster DH, Han C, Al-Nafussi A. Prognostic indicators for gastrointestinal stromal tumors: a clinicopathological and immunohistochemical study of 108 resected cases of the stomach. Histopathology 2003; 43: 118-126
37. Wu PC, Langerman A, Ryan CW, Hart J, Swiger S, Posner MC. Surgical treatment of gastrointestinal stromal tumors in the imatinib (STI-571) era. Surgery 2003; 134: 656-665
38. Yan H, Marchettini P, Acherman YIZ, Gething SA, Brun E, Sugarbaker PH. Prognostic assessment of gastrointestinal stromal tumor. Am J Clin Oncol 2003; 26: 221-228